For research and education only · Not reviewed by a medical professional · Disclaimer

← PepsRadar home

EXPLORE THE BIOLOGY

Peptides for Water Balance: What the Human Evidence Shows

Content updated · how dates work

Vasopressin pathways and fluid regulation.

This topic groups related research questions. Shared biology does not make different peptides interchangeable, or establish a clinical benefit. Compare each paper’s population, preparation, and measured outcome.

Water balance: what the human evidence shows

Each peptide is sorted by the strongest kind of human study among its profile’s selected studies, and the row shows what that study found and who was studied. A higher tier means stronger evidence exists, not that the peptide works for water balance: the best trial may be small, negative or about a different condition. No doses.

PeptideStrongest human evidence in our sourcesFDAHuman safety data
FDA-approved medicine (3)Approved for the specific uses on its label, which may not be this goal.
DesmopressinNocturia formulation study (2012) · Human randomized trial
Nighttime voiding decreased and the first sleep period lengthened. Clinically important low sodium occurred in some treatment groups.
Limitation: Formulation and patient selection matter. This study cannot supply instructions for a different desmopressin product, and fewer bathroom trips must be weighed against hyponatremia risk.
Studied: 757 adults in the intention-to-treat population, mostly with excessive nighttime urine production.
FDA-approvedFDA label
TerlipressinCONFIRM (2021) · Human randomized trial
Verified hepatorenal-syndrome reversal occurred in 32% versus 17%. At 90 days, deaths occurred in 51% versus 45%; respiratory-disorder deaths occurred in 11% versus 2%.
Limitation: Improvement in the specified kidney-function endpoint did not demonstrate a survival advantage. Serious respiratory harms are essential context for the result.
Studied: 300 adults with type 1 hepatorenal syndrome, randomized 199 to terlipressin and 101 to placebo.
FDA-approvedFDA label
VasopressinVASST (2008) · Human randomized trial
Mortality at 28 days was 35.4% versus 39.3% (P=0.26). At 90 days it was 43.9% versus 49.6% (P=0.11). Neither overall comparison was statistically significant.
Limitation: An apparent subgroup difference in less severe shock does not establish overall mortality superiority. Critical-care treatment context limits application to other populations.
Studied: 778 patients with septic shock who were already receiving vasopressors.
FDA-approvedFDA label

Selected studies, not a systematic review. Approval belongs to a specific product and use. Compare two side by side on the comparison pages.

Desmopressin

Desmopressin is a hormone analogue used in specific water-balance and related conditions. Its effects depend on the formulation and clinical setting.

Prescription medicines

Read the studies →

Terlipressin

Terlipressin is a vasopressin-related medicine used in a specific hepatorenal-syndrome setting. Its kidney-function results must be considered with the risk of serious respiratory complications.

Prescription medicines

Read the studies →

Vasopressin

Arginine vasopressin is a nine-residue hormone involved in water balance and vascular tone. VASST compared vasopressin with norepinephrine in septic shock.

Prescription medicines

Read the studies →

See something wrong on this page? Report a mistake · Corrections

FREE PEPSRADAR ACCOUNT

We check sellers’ lab reports with the testing labs themselves.

So far 89 of the 105 lab reports we looked up matched the testing lab’s own record, and 12 did not.

A free account shows which sellers, report by report, plus daily prices, deals, Ask PepsRadar and alerts. If you want it, the PepsRadar Weekly brings new research and FDA news once a week. No dosing advice.

Create a free accountWhat members get →